+34 620 10 75 37info@nanbiosis.com

Posts by Nanbiosis

You are here : Home / Articles by Nanbiosis (Page 76)

Nanomedicine Summer School

The second Summer School in Nanomedicine coordinated by Simó Schwartz, Scientific Director of NANBIOSIS unit 20,  was held at Vall d’Hebron hospital on 28 and 29 September. Dr. Schwartz has been the president of the European Society for Nanomedicine (ESNAM), a European scientific society focused on the clinical application of nanomedicine. From this society tasks are carried out to promote the research and the use of nanomedicine in the health sector, as well as to facilitate the exchange of knowledge in this area at European level among all the actors involved, Academy, industry and entities regulators.

CIBER-BBN, partner of NANBIOSIS, as sponsor of ESNAM, has collaborated in the organization of this event. Lectures were given by some Scientific Directors  or Coordinators  of NANBIOSIS units as Jaume Veciana, Ibane Abasolo, Laura Lechuga and Antoni Villaverde .

Photos of the meeting can be viewed in this link.

• Read More

JUMISC, partner of NANBIOSIS, represents Spain in a European network of 22 countries

The Jesús Usón Minimally Invasive Surgery Centre (JUMISC), partner of NANBIOSIS toguether with CIBER-BBN,  leads a multidisciplinary European research network to improve present urinary stents and prevent their causes of failure.

The idea of creating the network was born from a research, started in 1999 by Doctor Soria, Researcher-Coordinator of the Endoscopic Surgery Area at the JUMISC and the promoter of the mentioned network, representing Spain.

His proposal has been supported by the European and Spanish Urology Association, and funded by the Horizon 2020 Program-Cost Actions (European Cooperation in Science and Technology)

The focus of this Action is to create a multidisciplinary team to identify the problems concerning the urinary stents (design, composition, biomaterial applications, coatings, incrustation, etc.) and to promote future research on this field. In this way, the network will try to reduce adverse effects provoked by the present stents.

This European network (2017-2021), coordinated by Dr. Soria, the Chair of the Action, is composed by 22 European countries and other proposals coming from USA,  Japan, South Korea,  Israel, Canada, Russia, India and it is open to other invited countries to cooperate inside  the organised working groups.

This action will provide, during the next 4 years, an extensive and interdisciplinary R&D program to discover the causes of failure of the present stents and will propose cooperative work in urology and bioengineering field.

This proposal, an initiative of the JUMISC, leaded by Doctor Sánchez Margallo, will contribute to improve healthy-quality of patients, reduce in health care costs, and increase the competitiveness of the European medical device industry.

• Read More

New Zealand White rabbit as a model for preclinical studies addressing tissue repair at the level of the abdominal wall.

Juan Manuel Bellón and Gemma Pascual, Scientific Director and Coordinator of Unit 17 of NANBIOSIS, have recently published an article in the prestigious journal Tissue Eng Part C Methods.

Once a prosthetic material is implanted, an inflammatory reaction is induced in an attempt to remove it or isolate it from the host tissue. After this initial response, a cellular response takes place that gives rise to the start of the process of integration of the biomaterial within the host tissue. Immunohistochemical studies can provide information on the events that regulate this process, and are useful to analyze the progression of the implant and the neoformed tissue. For the tissue repair of a damaged area constantly subjected to tensile forces such as the abdominal wall, optimal collagenization is an extremely important factor. The proper deposition and organization of mainly collagen type I in the neoformed scar tissue will condition the mechanical strength and compliance of the repair zone and thus possible hernia recurrence. In this report, we review the use of the New Zealand White rabbit as the experimental animal for several models of abdominal wall repair and among other techniques, collagen component of the implants was assessed by immunofluorescence using anti-collagen type I and type III monoclonal antibodies. Samples were examined using a confocal microscope Leica SP5 belonging to the platform ICTS ‘NANBIOSIS’ U17 of the CIBER-BBN at the University of Alcalá.

Important information gained from selected models was observed in terms of tissue ingrowth and collagen deposition in the implant area showing significant differences depending on the properties of the implanted prosthetic material. Some variations were also observed in biomechanical properties according to the components comprising each prosthetic material.

• Read More

Best Abstract award at the European Society for Surgical Research meeting

Verónica Gómez-Gil, collaborator in Unit 17 of NANBIOSIS and the GITBIT-UAH group (CIBER-BBN), has been the first prizewinner in the Best Abstract Competition  at the symposium “New horizons in prevention and treatment of adhesions” organized by the Dutch Adhesion Group (DAG) at the 52nd meeting of the European Society for Surgical Reseach (ESSR). The ESSR 2017 meeting was held in Amsterdam from 14th till 17th June. The title of the abstract, presented as a quick-shot presentation and a full oral during the congress, was: An experimental adhesiogenic model to evaluate histological events over time in the omentum during adhesion formation.

This work shows that distribution of soluble and membrane-bound form of betaglycan, together with the expression of TGF-β1 and TGF-β3 at each time point after adhesion formation, are key factors to the cytoarchitecture and composition of omental adhesion tissue. These findings are of interest in the design of new adhesion prevention strategies.

• Read More

CIBER-BBN, partner of NANBIOSIS, leads the European initiative Nano4p, reference in Nanomedicine

CIBER-BBN along with other leading partners from various European countries, are setting up the “Precision Nanomedicine for People (Nano4P)” Flagship Initiative (www.Nano4P.eu).

Nano4P aims to develop material science and nanotechnology-based highly precise tools for the detection and tailored treatments of diseases, based on the unique characteristics of each person and taking advantage of stratification and molecular-level information. In this way, the paradigm shift that is already becoming visible in the healthcare system, will definitively enable to move from traditional treatment of diseases by existing drugs/tools, towards a predictive, preventive, precise and participatory (4P) medicine.

FET-Flagship Initiatives tackle grand science and technology (S&T) challenges. To get the expected outcome and an added value to Europe, the close collaboration of a large number of different scientific disciplines, industries, public regulatory agencies and nanosafety agents is mandatory. To date, only two initiatives of this FET-Flagship program have been developed, one of them, the Graphene project, with the participation of some CIBER-BBN groups and NANBIOSIS Unit 8.

We cordially invite you to support the FET-Flagship Initiative Nano4P by fulfilling the online template in the SUPPORT NANO4P section (http://www.nano4p.eu/support.php) of NANO4P website (http://www.nano4p.eu/). The interplay of all of us will definitively strength the Nano4P Initiative to build a network of excellence leading from the invention and development of disruptive technologies to the needs of the European society.

Thanks in advance for your interest and support.

 

 

• Read More

NANBIOSIS at the EATRIS Conference Translational Medicine 2017

NANBIOSIS  has actively participated in the third bi-annual conference organised by EATRIS, (the European infrastructure for translational medicine) in Prague on 24-26 of September Translational Medicine 2017: Enhancing predictivity in medicines development . The event gathered a wide range of stakeholders (industry, academia, policymakers) and focussed on bringing together the latest approaches to increase chances of success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.

Jesús Izco, Coordinator of NANBIOSIS, presented NANBIOSIS initiatives of joint collaboration, which were well received and will be coordinated and developed during the next months.

• Read More

NANBIOSIS organizes a forum for researchers and companies. Dates (probably February 2018) and location (probably Madrid) will be announced soon.

NANBIOSIS organizes a forum for researchers and companies. Dates (probably February 2018) and location (probably Madrid) will be announced soon.

The theme of the Forum is INTELLIGENT BIOMATERIALS / FUNCTIONALIZATION AND BIOMEDICAL DEVICES FOR APPLICATIONS IN REGENERATIVE MEDICINE AND DRUG DELIVERY.

The forum is presented through 2 sessions:

• First session: Short interventions of the latest advances and developments in the lines of research developed by the groups and platforms of Nanbiosis and description of the needs and demands of industry in that area. The companies and groups that request it will be able to have about 10 ‘to present their lines of research and / or needs and demands in relation to the thematic of the forum.
• Second session: Bilateral company-group / platform meetings to identify possible collaborations. These meetings will be pre-scheduled on request.

If you are interested in participating, contact Eduard Farré (628.943.198, efarre@arvor-ing.com) or with Jesús Izco (679.490.537, jmizco@ciber-bbn.es).

 

• Read More

II MASTER ON ENDOSCOPY AND MINIMALLY INVASIVE SURGERY IN SMALL ANIMALS (CEyCMI). EXTRAORDINARY DEADLINE FOR ADMISSIONS

A new extraordinary deadline for admissions to the II MASTER ON ENDOSCOPY AND MINIMALLY INVASIVE SURGERY IN SMALL ANIMALS has been set up, from 1st to 14th September. It is organised in collaboration with the Extremadura University ant takes place in Jesús Usón Minimally Invasive Surgery Centre as affiliated entity, offering 60 ECTS-credits.Necessary requirements include having a Veterinary studies degree and a B1 English Certificate. The Master will be held during the academic calendar 2017-2018, according to the established program, that will promote the interaction with the students via an on-line training platform, the direct contact with professors and experts, as well as offering an open material repository.

The Master consists on 4 hands-on training sessions at the JUMISC’s, an external stage in one of our partners centre and the Master’s degree final project.

Further info: www.ccmijesususon.com/ceycmi2017

• Read More

Gold nanoparticles can activate drugs inside tumors

Jesus Santamaría, Scientific Director of Unit 9 of NANBIOSIS has participated in a study that shows the ability of gold nanoparticles to generate in situ potent anticancer drugs from inert molecules thanks to a mechanism of elimination of terminal chemical groups that nanometric gold is able to catalyze. Gold is ideal for this catalytic role due to its high biocompatibility.

These results, published in the journal Angewandte Chemie, offer new hope in the fight against cancer and have been obtained thanks to the collaboration of scientists of Unit 9 of NANBIOSIS and, Víctor Sebastián, Silvia Irusta and Jesús Santamaría, with researchers from the Center for Cancer Research at the University of Edinburgh, led by Dr. Unciti-Broceta.

The work reveals the possibility of carrying out catalysis in biological means using tiny particles of gold. These gold nanoparticles, camouflaged in a resin microcapsule implanted in the brain of a zebrafish, have succeeded in catalyzing a chemical reaction generating fluorescent compounds.

Significant practical importance

“The main problem of chemotherapy treatments are the side effects in various organs due to the toxicity of the molecules that are used to fight cancer. For this reason, alternative routes are explored from nanotechnology, for example, transporting drugs to the tumor using nanoparticles or alternative treatments to drugs, such as hyperthermia, elevation of local temperature, obtained with nanoparticles”, says Jesús Santamaría.

The conclusions of this work suggest a different way: the drug would be supplied to the patient in its inert form and only converted to the toxic form locally, thanks to the catalysis of the nanoparticles that a surgeon would implant in the tumor.

 

Article of reference

Pérez-López, A. M., Rubio-Ruiz, B., Sebastián, V., Hamilton, L., Adam, C., Bray, T. L., Irusta, S., Brennan, P. M., Lloyd-Jones, G. C., Sieger, D., Santamaría, J. and Unciti-Broceta, A. (2017). “Gold-Triggered Uncaging Chemistry in Living Systems”. Angew. Chem. Int. Ed.. doi:10.1002/anie.201708379

• Read More

Nanomedicine applied to Dermatology by Almirall, Leitat Technology Center & NANOMOL (NANBIOSIS U6)

NANOMOL (ICMAB-CSIC), a research group member of ICTS “NANBIOSIS”, more specifically of the Biomaterial Processing and Nanostructuring Unit (U6), announced today the launch of Nano4Derm, a research project in collaboration with Almirall, S.A and Leitat Technology Center, focused in nanomedicine applied to treat dermatological diseases. Within the framework of this research project, new innovative formulations containing nanoencapsulated active ingredients will be developed for the topical treatment of inflammatory skin conditions, such as Acne and Psoriasis.

Nano4Derm involves the development and physico-chemical and biological characterisation of nanocapsules containing active ingredients, and the generation of scalable formulation prototypes for manufacturing nanoformulations suitable for clinical trials. These innovative formulations will address current unmet needs and challenges, such as antimicrobial resistance, and provide improved topical treatments for Acne and Psoriasis, in terms of side effects, instability of active ingredients, and skin penetration.

Under the terms of the agreement, ICMAB-CSIC and Leitat research centers will be in charge of developing the different prototypes of nanocapsules containing the active ingredients while Almirall will be responsible for the development of formulations containing the encapsulated actives. Furthermore, Almirall and Leitat will evaluate in preclinical studies both the new nanocapsules and formulations in order to select the best solution to address the unmet medical needs in the topical treatment of Acne and Psoriasis.

This agreement will lead to the development of two types of nanocapsules: Quatsomes and Polymeric Nanocapsules. Quatsomes are lipid nanoparticles with higher colloidal stability than liposomes, which favors the production of high quality, pharmaceutical formulations. They are obtained from the DELOS-SUSP, a technology developed by researchers from the Nanomol group (ICMAB-CSIC) based on the use of supercritical fluids such as CO2. This technology has advantages over other manufacturing methodologies in terms of homogeneity and scalability, as it replaces the use of organic solvents by green solvents. Polymeric Nanocapsules are developed by the Leitat Technology Center, and provide versatility to the project as they can be designed with different drug release profiles depending on the needs being addressed.

This project is funded by the Spanish Ministry of Economy, Industry and Competitiveness (MINECO) through the announcement of the State Program for R&D&i (2016), orientated to the Society Challenges, modality RETOS-Collaboration 2016, and co-financed by FEDER funds from the European Commission.

 

About Nanomol (ICMAB-CSIC)

NANOMOL is a research group depending on the Institute of Material Science of Barcelona from CSIC, with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. NANOMOL is also a member of Biomedical Research Networking center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and of the technology transfer network TECNIO from ACC1Ó-Generalitat de Catalunya. The development by Nanomol of the different prototypes of nanocapsules will be performed in the ICTS “NANBIOSIS”, more specifically by the Biomaterial Processing and Nanostructuring Unit (U6) of the CIBER in Bioengineering, Biomaterials & NanomedicIne located at the ICMAB-CSIC.

 

About Leitat

Leitat is a multisectoral private technological center whose mission is to collaborate with companies and other entities to create economic, social and sustainable value, through R+D+2i projects and technological processes from innovation and creativity. Leitat is a brand of the private entity Acondicionamiento Tarrasense and is recognized by the Generalitat de Catalunya (ACCIÓ) and by MINECO.

The Division of Nanomedicine and nanobiosensors of Leitat develops nanosystems for therapeutic application in order to solve specific problems in safety and, absorption issues and improvement of the efficacy of some API. In addition, related to diagnosis the group develops nanoparticles for specific recognition of analytes for the improvement of the sensitivity and signal amplification of biosensor systems.

The Efficacy and Safety Unit of Leitat also participates in Nano4Derm project, which has extensive experience in the development and application of in vitro models for the toxicological and efficacy evaluation of diverse natural products, from the pharmaceutical, chemical, cosmetics and food industries. In the pharmaceutical sector, the Unit acts as a strategic provider in Drug Discovery and pharmaceutical development processes. In recent years this unit has been involved in the development and biological characterisation of micro- and nano-delivery systems for topical application.

 

About Almirall

Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.

Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2,000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

• Read More